GlassScriptPhysician profile
Michael Lotfi
NPI 1811994296
$3,252.55
in general payments reported to CMS, 2019-2025
25 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $221 · 2021: $169 · 2022: $152 · 2023: $495 · 2024: $991 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $386.16 | 2019-2024 | Jynarque |
| Medtronic USA, INC. | $365.06 | 2019 | |
| Amgen INC. | $360.33 | 2021-2025 | Krystexxa, Parsabiv, Tavneos |
| Calliditas Therapeutics US INC. | $329.29 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $294.65 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $273.69 | 2023-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.98 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $149.70 | 2023-2025 | |
| Organogenesis INC. | $114.99 | 2019 | |
| Lilly USA, LLC | $102.78 | 2023-2024 | Mounjaro, Jardiance |
| Fresenius USA Marketing, INC. | $81.47 | 2020-2024 | Velphoro |
| Ardelyx, INC. | $65.82 | 2024 | Ibsrela |
| Vifor Pharma, INC. | $60.09 | 2021-2024 | Veltassa |
| Travere Therapeutics, INC. | $59.99 | 2024 | |
| Akebia Therapeutics INC | $59.55 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.25 | 2025 | |
| Baxter Healthcare | $45.03 | 2022-2023 | Renal - Pd |
| Janssen Pharmaceuticals, INC | $41.26 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $38.52 | 2022-2023 | Benlysta |
| Vantive US Healthcare LLC | $31.42 | 2025 | Renal - Pd |
| Ani Pharmaceuticals, INC. | $30.83 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $22.07 | 2023 | Krystexxa |
| Avion Pharmaceuticals | $18.46 | 2020 | |
| Aurinia Pharma U.S., INC. | $15.98 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.18 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lotfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.